Funder
BeiGene
Novartis Pharmaceuticals Corp
F Hoffmann-La Roche Ltd
Reference9 articles.
1. ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Lordick;Ann Oncol,2022
2. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma;Moehler;Eur J Cancer,2022
3. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types;Maule;J Immunother Cancer,2022
4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021
5. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: final analysis results of the RATIONALE-305 study;Xu;Ann Oncol,2023